Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD

Chest

Volumn 140, Issue 1, 2011, Pages 91-99

  Bernasconi, Maurizio ^a   Tamm, Michael ^a   Bingisser, Roland ^a   Miedinger, David ^a   Leuppi, Jörg ^a   Müller, Beat ^b   Christ Crain, Mirjam ^a   Stolz, Daiana ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; MIDREGIONAL PROATRIAL NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL; TIME OF DEATH;

EID: 79960410573     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-1353     Document Type: Article

References (51)

1. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946. (Pubitemid 38807371)
2. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science. 1996;274(5288):740-743. (Pubitemid 26398244)
3. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436- 1442. (Pubitemid 27212192)
4. Rabe KF, Hurd S, Anzueto A, et al; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555. (Pubitemid 47403272)
5. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867-874. (Pubitemid 44564786)
6. Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5):892-905. (Pubitemid 36592303)
7. Dolan S, Varkey B. Prognostic factors in chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2005;11(2):149-152. (Pubitemid 40279923)
8. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124(2):459-467. (Pubitemid 37000120)
9. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis. 1979;119(6):895-902. (Pubitemid 9208242)
10. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012. (Pubitemid 38269277)
11. Fujii T, Otsuka T, Tanaka S, et al. Plasma endothelin-1 level in chronic obstructive pulmonary disease: relationship with natriuretic peptide. Respiration. 1999;66(3):212-219. (Pubitemid 29259619)
12. Sheedy W, Stewart AG, Morice AH. Plasma levels of atrial natriuretic peptide and brain natriuretic peptide following intravenous saline infusion in oedematous chronic obstructive pulmonary disease and non-oedematous chronic obstructive pulmonary disease. Respiration. 1996;63(6):376-380. (Pubitemid 26356676)
13. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131(4):1058-1067. (Pubitemid 46608707)
14. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest. 2008;134(2):263-272.
15. Adnot S, Andrivet P, Chabrier PE, et al. Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion. J Clin Invest. 1989;83(3):986-993. (Pubitemid 19080633)
16. de Zeeuw D, Janssen WM, de Jong PE. Atrial natriuretic factor: its (patho)physiological significance in humans. Kidney Int. 1992;41(5):1115-1133.
17. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res. 1988;62(2):191-195. (Pubitemid 18041941)
18. Espiner EA, Richards AM, Yandle TG, Nicholls MG. Natriuretic hormones. Endocrinol Metab Clin North Am. 1995;24(3):481-509.
19. Weidmann P, Hasler L, Gnädinger MP, et al. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest. 1986;77(3):734-742. (Pubitemid 16067943)
20. Jin H, Yang RH, Chen YF, et al. Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats. J Appl Physiol. 1991;71(3):807-814.
21. Chen YF, Feng JA, Li P, Xing D, Ambalavanan N, Oparil S. Atrial natriuretic peptide-dependent modulation of hypoxia-induced pulmonary vascular remodeling. Life Sci. 2006;79(14):1357-1365. (Pubitemid 44215927)
22. Lordick F, Hauck RW, Senekowitsch R, Emslander HP. Atrial natriuretic peptide in acute hypoxia-exposed healthy subjects and in hypoxaemic patients. Eur Respir J. 1995;8(2):216-221.
23. Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest. 2008;133(5):1088-1094. (Pubitemid 351685510)
24. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9-19. (Pubitemid 46122969)
25. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204. (Pubitemid 17009877)
26. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001;37(2):386-391.
27. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5)(Suppl 2):398S-401S.
28. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natri uretic peptide in human plasma. Clin Chem. 2004;50(1):234-236. (Pubitemid 38125732)
29. Mazul-Sunko B, Zarkovic N, Vrkic N, et al. Pro-atrial natriuretic peptide hormone from right atria is correlated with cardiac depression in septic patients. J Endocrinol Invest. 2001;24(7):RC22-RC24.
30. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care. 2005;9(1):R37-R45.
31. Witthaut R. Science review: natriuretic peptides in critical illness. Crit Care. 2004;8(5):342-349. (Pubitemid 39468055)
32. Witthaut R, Busch C, Fraunberger P, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 2003;29(10):1696-1702. (Pubitemid 37373812)
33. Krüger S, Papassotiriou J, Marre R, et al; CAPNETZ Study Group. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med. 2007;33(12):2069-2078. (Pubitemid 350164580)
34. Prat C, Lacoma A, Dominguez J, et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect. 2007;55(5):400-407. (Pubitemid 47611511)
35. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, et al. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir Med. 2009;103(10):1548-1553.
36. Tanaka T, Kanda T, Takahashi T, Saegusa S, Moriya J, Kurabayashi M. Interleukin-6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes. J Int Med Res. 2004;32(1):57-61. (Pubitemid 38159231)
37. Hackett TL, Holloway R, Holgate ST, Warner JA. Dynamics of pro-inflammatory and anti-inflammatory cytokine release during acute inflammation in chronic obstructive pulmonary disease: an ex vivo study. Respir Res. 2008;9:47.
38. Chaouat A, Savale L, Chouaid C, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009;136(3):678-687.
39. Ogawa Y, Nakao K, Mukoyama M, et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res. 1991;69(2):491-500.
40. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159(1):158-164. (Pubitemid 29036519)
41. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62(5):411-415. (Pubitemid 46698390)
42. Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest. 2008;133(5):1088-1094. (Pubitemid 351685510)
43. Almagro P, Calbo E, Ochoa de Echagüen A, et al. Mortality after hospitalization for COPD. Chest. 2002;121(5):1441-1448.
44. Almagro P, Barreiro B, Ochoa de Echaguen A, et al. Risk factors for hospital readmission in patients with chronic obstructive pulmonary disease. Respiration. 2006;73(3):311-317. (Pubitemid 43725788)
45. Costello R, Deegan P, Fitzpatrick M, McNicholas WT. Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis. Am J Med. 1997;102(3):239-244. (Pubitemid 27202832)
46. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995;107(5):1193-1198.
47. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36(10):752-758. (Pubitemid 12249743)
48. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154(4 Pt 1):959-967.
49. Chavaillon JM, Lerousseau L, David P, et al. Intrahospital mortality during acute exacerbations of BPCO. Study EABPCO-CPHG of the College of the Lung specialists of General hospitals (CPHG) [in French]. Rev Mal Respir. 2010;27(7):709-716.
50. Bustamante-Fermosel A, De Miguel-Yanes JM, Duffort-Falcó M, Muñoz J. Mortality-related factors after hospitalization for acute exacerbation of chronic obstructive pulmonary disease: the burden of clinical features. Am J Emerg Med. 2007;25(5):515-522. (Pubitemid 46818847)
51. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303(23):2359-2367.